



**POWERFUL**  
BREAKTHROUGHS  
2020 Annual Report



## MISSION

*To bring hope to cancer patients  
through innovative clinical trials  
while advancing treatment for  
patients in the future.*

**POWERFUL**  
BREAKTHROUGHS

---

A MESSAGE FROM THE  
CHAIRMAN OF THE BOARD

BY THE NUMBERS

FINANCIALS

DONOR IMPACT

**A MESSAGE FROM ROY LAMKIN**  
*Chairman of the Board*

---

*Expanding Our Ability to Provide HOPE to Cancer Patients  
Now and In the Future*

In 2020 our dedicated team of professionals fought through the limitations and risks of the pandemic to successfully offer substantially more trials to more patients than ever in our history. By continuously focusing on our safety standards and working closely with pharmaceutical firms to be nimble and innovative, our team was able to provide uninterrupted care to existing and new cancer patients while many universities and independent cancer research centers had to curtail or even stop offering current or new treatments.

Led by the close coordination between our executive team and the board, we have continued to strengthen our ability to respond to opportunities. Operationally and financially, we have refined our ability to maximize the impact of philanthropic gifts to enable us to provide more trials to more patients in an industry-leading turnaround time. In direct support of this, EVERY Board member is directly involved on at least one of our board committees and is an active donor and passionate about our Mission of providing HOPE to cancer patients.


Organizationally, our team is experienced, dedicated, and committed to continuously improving our ability to be responsive and effective in providing the right trials to a broad array of patients. As we enter 2021, we look forward to an era of expanded opportunity to provide HOPE to more cancer patients throughout the metroplex and beyond. Achievements in 2020 have strengthened Mary Crowley's ability to offer HOPE to more patients, in more locations, in both organ-specific and genomic trials, than ever before.

I encourage you to learn more about Mary Crowley and to explore what Mary Crowley is doing to "bring HOPE to cancer patients through innovative clinical trials while advancing treatment for patients in the future."



Roy Lamkin

BY THE NUMBERS



16,900,000+

US ADULTS AND CHILDREN  
ARE CANCER SURVIVORS<sup>1</sup>

OVERALL CANCER DEATH  
RATES DECLINE

FROM 1991- 2018  
CANCER DEATH RATES DROPPED BY  
**31%**<sup>1</sup>



745

# OF CLINICAL  
TRIALS CONDUCTED  
1997-2020



7363

# OF PATIENTS  
ENROLLED  
1997-2020



111

YEARS OF EXPERIENCE  
ACROSS MCCR  
INVESTIGATORS



18

FDA-APPROVED  
CANCER DRUGS STUDIED  
AT MARY CROWLEY

- |              |                  |
|--------------|------------------|
| 1. BAVENCIO  | 10. CAMPOSTAR    |
| 2. ROZLYTREK | 11. IMFINZI      |
| 3. LIBTAYO   | 12. PEMAZYRE     |
| 4. CABOMETYX | 13. SOTORASIB    |
| 5. LYNPARZA  | 14. NIRAPARIB    |
| 6. NINLARO   | 15. TAZEMETOSTAT |
| 7. PROVENGE  | 16. ABEMACICLIB  |
| 8. YERVOY    | 17. LENVIMA      |
| 9. IMLYGIC   | 18. YONDELIS     |



TOP TEN TUMOR TYPES TESTED  
AT MARY CROWLEY

- |                        |                       |
|------------------------|-----------------------|
| 1. COLON & RECTAL      | 6. ENDOMETRIAL        |
| 2. PANCREATIC          | 7. SARCOMA            |
| 3. NON-SMALL CELL LUNG | 8. CERVICAL           |
| 4. OVARIAN             | 9. CHOLANGIOCARCINOMA |
| 5. PROSTATE            | 10. SMALL-CELL LUNG   |



PARTNERED WITH **293**

LEADING GLOBAL  
PHARMACEUTICAL COMPANIES



130

FIRST IN HUMAN TRIALS  
CONDUCTED AT MARY CROWLEY

450

NEW PATIENT REFERRALS



3030+  
PATIENT VISITS  
IN 2020



<sup>1</sup> Cancer Statistics 2019, National Cancer Institute

**MARY CROWLEY MEDICAL RESEARCH CENTER AND AFFILIATES**  
**CONSOLIDATED STATEMENT OF FINANCIAL POSITION**

As of December 31, 2020 and 2019

<i>Assets</i>		
	<b>2020</b>	<b>2019</b>
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$ 3,974,872	\$ 2,944,760
Investments in securities	1,496,579	1,375,415
Accounts receivable	5,950,044	4,293,161
Contributions receivable	72,175	74,675
Prepaid expenses & other current assets	42,520	55,693
<b>Total current assets</b>	<b>11,536,190</b>	<b>8,743,704</b>
<b>PROPERTY AND EQUIPMENT (NET)</b>	<b>201,758</b>	<b>249,164</b>
<b>OTHER ASSETS</b>		
Deposits	30,432	30,432
<b>Total other assets</b>	<b>30,432</b>	<b>30,432</b>
<b>TOTAL ASSETS</b>	<b>11,768,380</b>	<b>9,023,300</b>
<i>Liabilities and Net Assets</i>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	533,726	799,235
Accrued expenses	717,191	336,390
Contract liabilities	68,469	276,706
<b>Total current liabilities</b>	<b>1,319,386</b>	<b>1,412,331</b>
<b>LONG TERM LIABILITIES</b>		
SBA loans	<b>10,000</b>	
<b>Total liabilities</b>	<b>1,329,386</b>	<b>1,412,331</b>
<b>NET ASSETS</b>		
Without donor restrictions	8,582,949	5,777,969
With donor restrictions	1,856,045	1,833,000
<b>Total net assets</b>	<b>10,438,994</b>	<b>7,610,969</b>
<b>TOTAL LIABILITIES AND NET ASSETS</b>	<b>11,768,380</b>	<b>9,023,300</b>

## MARY CROWLEY MEDICAL RESEARCH CENTER AND AFFILIATES CONSOLIDATED STATEMENT OF ACTIVITIES

For the Year Ended December 31, 2020  
With summarized financial information for the year ended December 31, 2019

	Without Donor Restriction	With Donor Restriction	Total All Funds	
			2020	2019
<b>SUPPORT AND REVENUE</b>				
Revenue from contracts with customers				
Research revenue	\$10,102,994	\$831,744	\$10,934,738	\$8,185,648
Contributions and grant revenue	233,703	705,637	939,340	1,172,005
Interest income	33,322	-	33,322	51,719
PPP Loan	1,237,000		1,237,000	
Realized gain on investments	20,431	-	20,431	16,941
Unrealized gain (loss) on investments	85,611	-	85,611	213,386
Net assets released from restrictions	1,514,336	(1,514,336)	-	-
<b>Total support and revenue</b>	<b>13,227,397</b>	<b>23,045</b>	<b>13,250,442</b>	<b>9,639,699</b>
<b>OPERATING EXPENSES:</b>				
Program				
Medical & research	8,072,388	-	8,072,388	7,181,812
General & administrative	1,965,576	-	1,965,576	1,755,162
Fundraising	389,257	-	389,257	371,787
<b>Total operating expenses</b>	<b>10,427,221</b>	<b>-</b>	<b>10,427,221</b>	<b>9,308,761</b>
Changes in net assets from operations	2,800,176	23,045	2,823,221	330,938
Other income (expense)	4,804	-	4,804	5,703
<b>INCREASE (DECREASE) IN NET ASSETS</b>	<b>2,804,980</b>	<b>23,045</b>	<b>2,828,025</b>	<b>336,64</b>
<b>NET ASSETS, beginning of period</b>	<b>5,777,969</b>	<b>1,833,000</b>	<b>7,610,969</b>	<b>7,274,328</b>
<b>NET ASSETS, end of period</b>	<b>8,582,949</b>	<b>1,856,045</b>	<b>10,438,994</b>	<b>7,610,969</b>

## **Donor Spotlight: Pushing Hope** ***Annual Marine Industry Charity Tournament***

Each year, a big pink barge catches everyone's eye as it makes its way up and down the Mississippi River. Painted a bright, attention-grabbing pink, there is no missing its striking color as the Big Hope I glides through muddy waters. For Ceres Consulting LLC and Ceres Barge Line employee Vince Schu, that's exactly the point.

In 2012, Vince came up with the idea for Ceres to support cancer research. Vince's family had been deeply affected by cancer, as had many of his colleagues and friends in the barge industry. The Ceres team enthusiastically agreed, and they decided to paint a barge bright pink and name it Big Hope I to raise cancer awareness. Sherwin-Williams generously agreed to donate the signature bright pink paint, and Jeffboat Shipyard agreed to paint the barge. Thus, Ceres launched Big Hope I, the big pink barge, to raise cancer awareness within the barge and towing industry.

"The marine industry is a group of individuals who do not sit back and wait for someone else to solve a problem. Instead, we take the problem on head first and try to tackle it with whatever resources we have available," Ceres Officers Mark Fletcher and Mark Mestemacher explain. "BIG HOPE I unites and rallies the inland river and coastal regions and affiliated industries in fighting a disease that strikes all ages, races and genders without remorse. This fundraising effort shows firsthand how that 'can-do' attitude can work toward a common good."

In fact, Ceres goes beyond simply raising awareness by raising funds to support clinical trials at Mary Crowley Cancer Research. Each year, they host the the Pushing Hope Annual Marine Industry Charity Tournament, a fun weekend featuring a seafood boil, golf tournament, softball and kickball tournaments, and a 5K Fun Run. Members of the barge industry all over the country gather in support of their family and friends who have been affected by cancer, while enjoying a chance to socialize with their associates.

Thanks to the generous efforts of Ceres and the rest of the barge industry, the Big Hope I initiative has raised almost \$1.5 million since 2012. Mary Crowley is so grateful for their support, which has allowed us to open even more clinical trials and support countless patients. Because of Big Hope I, new cancer treatments have been approved by the FDA and are now available to all cancer patients that were not available previously. Cancer patients have hope everyday thanks to Big Hope I!



## DONOR SUPPORT: *The Impact You Make*



Deborah Montonen, CFRE  
Vice President and Chief Development Officer

I wanted to take this moment to thank all of the wonderful donors that contributed to Mary Crowley Cancer Research in 2020. Even though we were all still in “pandemic mode”, we had a very good year due to your generosity. Events were not able to be held in person, but we still had support from you financially with our virtual events. As we look forward to 2022, we do have some exciting plans and hope you will participate in those.

As always, we could not do it without you. On behalf of the board, the staff, and most of all, the patients, THANK YOU! You are truly appreciated!

*When I needed hope,  
Mary Crowley  
Cancer Research  
was there.*

Judith Frye, Patient



## OUR LEADERSHIP

Jon Friedenber, Chief Executive Officer  
Minal Barve, M.D., Executive Medical Director  
James Strauss, M.D., Clinical Scientific Director  
Deborah Montonen, CFRE, Vice President and Chief Development Officer  
Jeanne Jones, RN, MSN, Vice President of Clinical Operations  
Angela Ebel, Vice President of Budgeting  
Jennifer Sala, MBA, Vice President of Compliance  
Amber Craft, MBA, Vice President of Accounting

## BOARD OF TRUSTEES

Roy Lamkin, Board Chair  
Ellen Harding, Vice Chair  
Adil Adi  
Marilyn Augur  
Scott Bradley Burris, M.D.  
Vincent Bush  
Edwin Flores, J.D., Ph.D  
Thomas B. Hoyt  
Michael Kearins  
Ashley E. Ross, M.D., Ph.D.  
Mary Elizabeth Warner, J.D.

## MEDICAL STAFF

Minal Barve, M.D., Executive Medical Director  
James Strauss, M.D., Clinical Scientific Director  
Reva Schneider, M.D., Physician Investigator  
Jairo Olivares, M.D., Physician Investigator  
Douglas Orr, M.D., Physician Investigator  
Maurizio Ghisoli, M.D., Physician Investigator  
Leah Plato, P.A., Associate Director of Clinical and Scientific Operations  
Zoey Sayi, Nurse Practitioner  
Jennifer Ashun, Nurse Practitioner